
|Articles|October 1, 2003
Biologics Seek 'Equal Footing' to Current Therapy
New York - The safety and efficacy of the new biologic agents for psoriasis suggest a new treatment strategy that departs from the current stepwise approach, according to Craig L. Leonardi, M.D., clinical associate professor of dermatology, Saint Louis University School of Medicine in Missouri.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
3
JAK Inhibitors Show Comparable Safety to TNF Antagonists
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















